Targeting the PI3K Pathway in Malignant Glioma

靶向恶性胶质瘤中的 PI3K 通路

• 批准号: 9339981
• 负责人: W K ALFRED Yung
• 金额: $ 24.25万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9339981
• 关键词: 1-Phosphatidylinositol 3-Kinase; Address; Aftercare; Animals; Bayesian Method; Behavior; Biological; Biological Markers; Cell Line; Cell Proliferation; Cell model; Cells; Clinic; Clinical Trials; Combined Modality Therapy; Companions; Data; Data Set; FRAP1 gene; Failure; Frequencies; Funding; Gene Mutation; Gene Targeting; Genomics; Glioblastoma; Glioma; Grant; Growth; Human; In Vitro; Individual; Malignant Glioma; Malignant neoplasm of brain; Metabolism; Methods; Modeling; Molecular; Molecular Profiling; Operative Surgical Procedures; Pathologic; Pathway interactions; Patient Selection; Patients; Pattern; Phase I Clinical Trials; Population; Proteins; Proteomics; RNA Interference; Randomized; Recurrence; Regulatory Pathway; Role; Sampling; Signal Pathway; Signal Transduction; Specimen; Stem cells; Testing; The Cancer Genome Atlas; Therapy trial; Time; Treatment Failure; Treatment outcome; Up-Regulation; Validation; angiogenesis; arm; base; cancer stem cell; cancer therapy; combinatorial; design; experience; improved; in vivo; inhibitor/antagonist; kinase inhibitor; knock-down; malignant phenotype; patient biomarkers; profiles in patients; resistance mechanism; response; small hairpin RNA; small molecule inhibitor; stem-like cell; targeted agent; targeted cancer therapy; tumor